In a recently completed Phase 2 clinical study (November 28, 2007), data indicated that treatment at the erythema or papule/edema stages resulted in a statistically significant effect on the herpetic episode. In particular, the study demonstrated a 79 percent increase in aborted lesions (43% active; 24% placebo; p= 0.03; active n= 61; placebo n= 72) in SoloVir(TM) ETS treated subjects versus placebo. These subjects also experienced a 3.5 day reduction in time to complete healing (p= 0.015). Furthermore, this study demonstrated a statistically significant and clinically meaningful reduction in pain. SoloVir(TM) ETS was shown to be well tolerated with a compliance rate greater than 98 percent, with no serious adverse events reported related to study drug in all groups.
Based on the strong clinical results from TPI-H-221, Transport will advance SoloVir(TM) ETS into its next clinical stage of development in 2008. Transport has retained worldwide rights to SoloVir(TM) ETS for the treatment of herpes labialis.
Transport is a Massachusetts-based, privately held specialty pharmaceutical company. Current venture investors include Quaker BioVentures, The Carlyle Group, The Hillman Company and The Halleran Company. For more information, please visit http://www.transportpharma.com.
|SOURCE Transport Pharmaceuticals|
Copyright©2007 PR Newswire.
All rights reserved